ImmunOs Therapeutics Presents Details of Novel Bispecific Anti-Tumor Molecules at ESMO Immuno-Oncology Congress 2023
December 11, 2023 04:00 ET | AKAMPION
HLA/SIRPa bispecifics targeting LILRB1/2 plus CD47 checkpoint receptorDesigned to target myeloid, NK and T cells and to be precisely directed to tumor sitesPotent in vitro anti-tumor efficacy...
Glycotope and Evotec enter licensing agreement to combine Glycotope antibodies and Evotec’s immune cell engager platform
December 11, 2023 02:00 ET | Glycotope
Glycotope and Evotec enter licensing agreement to combine Glycotope antibodies and Evotec’s immune cell engager platform Berlin, Germany, 11 December 2023 – Glycotope GmbH (Glycotope) has signed...
NOVARTIS logo.jpg
Latest Novartis Kisqali® NATALEE analysis reinforces 25% reduction in risk of recurrence across broad population of patients with early breast cancer; supports regulatory submissions
December 08, 2023 09:15 ET | Novartis Pharma AG
With 5.6 months of additional follow-up and 78.3% of patients having completed Kisqali® (ribociclib) investigational treatment, the updated analysis shows sustained iDFS benefit and stability in...
Emergen logo.png
Global Medical Imaging Market Size to Reach USD 52.03 Billion in 2032 | Emergen Research
December 07, 2023 09:10 ET | Emergen Research
Vancouver, Dec. 07, 2023 (GLOBE NEWSWIRE) -- The global medical imaging market, valued at USD 52.03 Billion in 2032, is set to experience substantial growth, with a projected revenue Compound Annual...
IVBM_121323_INGO_General (1)
The Institute for Value-Based Medicine® from The American Journal of Managed Care® hosts Shaping the Future of Cancer Care: A New Era of Innovative Therapies event in Tampa, Florida
December 06, 2023 16:58 ET | The American Journal of Managed Care
CRANBURY, N.J., Dec. 06, 2023 (GLOBE NEWSWIRE) -- The American Journal of Managed Care® (AJMC), the leading multimedia peer-reviewed journal dedicated to issues in managed care, is thrilled to...
CARGO Therapeutics Announces Scientific Advisory Board
December 06, 2023 08:05 ET | Cargo Therapeutics, Inc.
SAN MATEO, Calif., Dec. 06, 2023 (GLOBE NEWSWIRE) -- CARGO Therapeutics, Inc. (CRGX), a clinical-stage biotechnology company uniquely positioned to advance next generation, potentially curative cell...
Data Presented at SABCS Demonstrate the Significant Promise of Precede Biosciences’ Novel Liquid Biopsy Platform to Define HER2 and ER Status in Patients With Advanced Breast Cancer
December 06, 2023 08:00 ET | Precede Biosciences, Inc.
BOSTON, Dec. 06, 2023 (GLOBE NEWSWIRE) -- Precede Biosciences, a company impacting the development and use of precision medicines with a first-in-class liquid biopsy platform, today announced that...
Transparency Market Research
Contrast Media Market Size & Share to Surpass USD 7.8 billion by 2031 | Transparency Market Research, Inc.
December 06, 2023 04:00 ET | Transparency Market Research
Wilmington, Delaware, United States, Dec. 06, 2023 (GLOBE NEWSWIRE) -- Transparency Market Research Inc. - The contrast media market is expected to reach US$ 7.8 billion by 2031 from US$ 4.9 billion...
Arvinas and Pfizer Announce Interim Data from Phase 1b Trial of Vepdegestrant in Combination with Palbociclib (IBRANCE®) and Plans to Expand Vepdegestrant Development Program
December 05, 2023 13:33 ET | Arvinas Inc.
– Overall response rate of 42% and median progression-free survival of 11.1 months in heavily pre-treated patients (after 11 months median follow-up time and based on 48% of events) demonstrates the...
ALLARITY Full Color RGB 2023JUN07.png
Allarity’s Early Phase 2 Stenoparib Data Indicates Clinical Benefit in Women with Advanced Ovarian Cancer Selected with DRP® Companion Diagnostic
December 05, 2023 07:30 ET | Allarity Therapeutics, Inc.
All evaluable participants, with prior PARP inhibitor therapy and chemotherapy, showed significant tumor shrinkage including one complete response Early data follows Phase 2 dose optimization...